PD-1/PD-L1 blockade inhibits epithelial-mesenchymal transition and improves chemotherapeutic response in breast...

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Triple negative breast cancer (TNBC) therapies targeting the PD-1/PD-L1 axis show limited efficacy, suggesting alternative tumor-promoting roles.
• PD-L1 overexpression is linked to chemotherapy resistance in various cancers.

Purpose of the Study:

• To investigate the tumor-promoting role of the PD-1/PD-L1 axis in breast cancer.
• To evaluate the efficacy of PD-L1 inhibition in combination with chemotherapy.

Main Methods:

• Downregulation of PD-L1 using siRNA and pharmacological inhibitors.
• In vitro assays for tumor cell proliferation, invasion, migration, and T cell-mediated killing.
• In vivo studies combining PD-L1 inhibition with chemotherapy.

Main Results:

• PD-L1 downregulation suppressed tumor cell proliferation, invasion, and migration, enhancing T cell-mediated killing.
• Inhibition of PD-L1 improved the sensitivity of TNBC cells to chemotherapy.
• Combination therapy significantly reduced tumor progression by inhibiting epithelial-mesenchymal transition.

Conclusions:

• PD-L1 plays a significant role in breast cancer cell transformation and progression.
• Targeting PD-L1 is a promising therapeutic strategy for breast cancer, particularly in combination with chemotherapy.